Clinical Trial Update: Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) [Phase 2]

View source ↗

Summary

A Phase 2 trial update for lisocabtagene maraleucel (JCAR017) as second-line therapy in non-Hodgkin lymphoma has been completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Lisocabtagene maraleucel (lisocabtagene maraleucel)

Snippet

Sponsor: Juno Therapeutics, a Subsidiary of Celgene | Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin | Phase 2 | Status: COMPLETED | Results posted: 2022-12-29